Botulinum toxin type A as a novel method of preventing cleft lip scar hypertrophy—A literature review

Bartkowska, Patrycja; Roszak, Justyna; Ostrowski, Hubert; Komisarek, Oskar

doi:10.1111/jocd.13614

Cited by 8 publications

(13 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Botulinum toxin, released from Clostridium botulinum bacteria, is a neurotoxin that inhibits neuromuscular transmission indirectly. In spite of the presence of many types of botulinum toxin (A–F), botulinum toxin type A has been used extensively to improve facial wrinkles 19 . Moreover, it is known to minimize scarring and prevent skin contractions during healing by altering fibroblast signalling pathways 15 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

In‐vivo assessment of application of folinic acid and botulinum toxin A in cleft lip surgical defects

Shiva,

Soltani,

Moaddabi

et al. 2024

Orthod Craniofacial Res

View full text Add to dashboard Cite

IntroductionFolinic acid and botulinum toxin A have shown promising results in wound healing in different studies. This study aimed to compare the effects of these approaches on wound healing after simulating cleft lip surgery in rats.MethodsIn this experimental animal study, after creating lip defects, 30 rats were randomly divided into three groups and received normal saline (CTL), botulinum toxin A (BOT), and folinic acid (FOL). Biopsy from the skin wounds was performed after 14‐ and 28‐days. These samples were stained with haematoxylin and eosin and Masson trichrome staining. Finally, each pathological parameter of wound healing was rated in this study.ResultsWhile the inflammatory response was not different among the study groups, fibroblast proliferation and collagen deposition were significantly higher in FOL group compared to BOT group. Moreover, both BOT and FOL facilitated epithelial healing and 14‐day angiogenesis as compared with normal saline.ConclusionsImproved wound healing was observed using both botulinum toxin A and folinic acid in rat animal models. However, the application of botulinum toxin A caused less fibroblast proliferation and collagen deposition which can potentially lead to less scar formation, which can be particularly important in the aesthetic zone.

show abstract

Section: Introductionmentioning

confidence: 99%

“…In spite of the presence of many types of botulinum toxin (A-F), botulinum toxin type A has been used extensively to improve facial wrinkles. 19 Moreover, it is known to minimize scarring and prevent skin contractions during healing by altering fibroblast signalling pathways. 15 Folic acid (vitamin B9) participates in DNA synthesis and repair.…”

mentioning

confidence: 99%

In‐vivo assessment of application of folinic acid and botulinum toxin A in cleft lip surgical defects

Shiva,

Soltani,

Moaddabi

et al. 2024

Orthod Craniofacial Res

View full text Add to dashboard Cite

show abstract

“…A more expansive review of the literature 2 years prior by Bartkowska et al [31] looked at various studies showing unanimous improvements in VAS, VSS, and scar width measurements in the Botox-A administered study groups with no reported complications. Another factor leading to the formation of hypertrophic scars is the expression of transforming growth factor-β1 (TGF-β1) [32].…”

Section: Introductionmentioning

confidence: 99%

“…TGF-β1 causes proliferation of human fibroblasts, and ultimately the production of collagens I and III. Botox-A has been shown not only to downregulate TGF-β1, but also to promote the apoptosis of well differentiated fibroblasts [30,31]. One thing to note is that the dose of the toxin and the timing of the injections (before, during, or after surgery) differed between the studies examined [31].…”

Section: Introductionmentioning

confidence: 99%

Current trends in unilateral cleft lip repair

Hughes

Tatum

2023

Current Opinion in Otolaryngology &Amp; Head &Amp; Neck Surgery

View full text Add to dashboard Cite

The purpose of this review is to provide an in-depth look at the current perioperative and intraoperative practices for unilateral cleft lip repair. The contemporary literature reveals trends towards incorporation of curvilinear and geometric hybrid lip repairs. Perioperative practices are trending in new directions as well with the use of enhanced recovery after surgery (ERAS) protocols to reduce morbidity and length of stay, continued use of nasoalveolar molding, and a tendency to favor outpatient repair with more utilization of same day surgery centers. There is much room for growth, with new and exciting technologies on the horizon to improve upon cosmesis, functionality, and the operative experience.

show abstract

“…Since then, numerous studies have suggested that BTXA may be effective in suppressing scars in various parts of the body. In a recent review, Bartkowska et al 14 concluded that injecting BTXA appears to be a promising method in cleft lip scar management. However, this review lacks statistical data support.…”

Section: Introductionmentioning

confidence: 99%

Botulinum toxin type A for preventing and treating cleft lip scarring—A systematic review and meta‐analysis

Tang

et al. 2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Background Cleft lip and/or palate (CL/P) are congenital cleft facial deformities that are abnormal developments caused by errors in the fusion process of the embryo's face. Surgery is an important treatment, but postoperative scars will still cause psychological shadows to patients. This study aimed to systematically evaluate the efficacy of Botulinum toxin type A (BTXA) in preventing and treating postoperative CL/P scars and improving scar quality. Methods A systematic review was performed by searching PubMed, EMBASE, the Cochrane Library, and Web of Science for relevant trials. All relevant trials were performed before June 30, 2021. The data were entered into Revman 5.3 software, and a meta‐analysis was conducted by using the random‐effects model or fixed‐effects model. Results Four randomized controlled trials involving 161 cases were included. Through quantitative analysis, BTXA showed significant differences in preventing and treating postoperative CL/P scars in terms of scar width (MD: −0.20; [95% CI, −0.30, –0.10], p < 0.0001) and the Visual Analog Scale (VAS) (MD: 1.30; [95% CI, 1.06, 1.55], p < 0.0001), although no significant difference was noted on the Vancouver Scar Scale (VSS) (MD: −0.75; [95% CI, −1.68, 0.19], p = 0.12) between the two groups. Conclusion In preventing and treating postoperative CL/P scar hypertrophy, we found that BTXA injection can show better results. There was no statistically significant difference between the results after omitting Navarro's study or Chang's study because of the time of injection—before/during surgery or adult CL/P scars.

show abstract

Botulinum toxin type A as a novel method of preventing cleft lip scar hypertrophy—A literature review

Cited by 8 publications

References 27 publications

In‐vivo assessment of application of folinic acid and botulinum toxin A in cleft lip surgical defects

In‐vivo assessment of application of folinic acid and botulinum toxin A in cleft lip surgical defects

Current trends in unilateral cleft lip repair

Botulinum toxin type A for preventing and treating cleft lip scarring—A systematic review and meta‐analysis

Contact Info

Product

Resources

About